AE

Loading...

Biotech Showcase™ 2019: Lipid nanoparticle-encased TUSC2 gene underpins Phase II NSCLC asset

125 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jan 23, 2019

https://ebdgroup.knect365.com/biotech...
Gene therapies are currently one of the hottest therapeutic properties. Speaking on the sidelines of Biotech Showcase 2019, Julien Pham, President and COO of Genprex, describes to Mike Ward how the company is using a technology platform which wraps the TUSC2 gene in a cholesterol nanoparticle to create Oncoprex which, in combination with erlotinib, is in Phase II testing against NSCLC. Genprex also plans to start a Phase I trial of Oncoprex plus immunotherapies in the near future.

Comments are turned off

to add this to Watch Later

Add to

Loading playlists...